Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

finance.yahoo.com · 2026-08-31

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis Pharma’s Yuviwel (navepegritide, developed as TransCon CNP) is a once-weekly prescription injection approved by the FDA to increase linear height growth in children aged 2 years and older with achondroplasia who have open growth plates. In March, the FDA approved Yuviwel, the first and only once-w

TickrTrends take: Ascendis Pharma's resolution of global patent disputes with BioMarin removes a significant source of litigation risk that could have affected the company's financial resources and operational focus going forward. With this uncertainty cleared, investors evaluating ASND should monitor whether the company can now redirect attention and capital toward its pipeline development and commercialization efforts, which would be relevant factors for establishing a complete valuation once TickrTrends completes its analysis. The settlement's terms and any financial implications will be important to track as they may influence the company's cash position and growth trajectory in the Healthcare sector.

Read the full story at finance.yahoo.com →